D. Pavlov

发表

Comorbidity as a Predictor of Stage of Illness for Patients With Breast Cancer

B. Newman, Kun Chen, S. Fleming, 2005, Medical care.

Phase I/II trial of tremelimumab in patients with metastatic melanoma.

B. Redman, J. Sosman, J. Kirkwood, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long‐term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome‐positive leukemias treated with bosutinib

T. Brümmendorf, H. Kantarjian, J. Cortes, 2016, American journal of hematology.

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

K. Harrington, N. Lee, R. Ferris, 2021, The Lancet. Oncology.

Overall survival analysis from a randomized phase II study of axitinib with or without dose titration for first-line metastatic renal cell carcinoma.

E. Jonasch, M. Fishman, B. Melichar, 2015 .

Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma

A. Hauschild, A. Ribas, C. Punt, 2008 .

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

T. Brümmendorf, H. Kantarjian, J. Cortes, 2014, American journal of hematology.

Assessment of Early Molecular Response As a Predictor of Long-Term Clinical Outcomes in the Phase 3 BELA Study

T. Brümmendorf, H. Kantarjian, J. Cortes, 2012 .

Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma

A. Ribas, J. Reuben, L. Camacho, 2005 .

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

B. Comin-Anduix, A. Ribas, J. Reuben, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Standardized human bone marrow-derived stem cells infusion improves survival and recovery in a rat model of spinal cord injury

B. Cillero-Pastor, T. Strekalova, G. Brook, 2019, Journal of the Neurological Sciences.

Survival of patients (pts) with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in a phase I/II study

B. Redman, J. Sosman, J. Kirkwood, 2007 .

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

A. Hauschild, G. Linette, J. Kirkwood, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.

E. Jonasch, M. Fishman, B. Melichar, 2013, The Lancet. Oncology.

Association of adverse events and tumor response in melanoma patients treated with tremelimumab.

D. Pavlov, M. Marshall, 2010 .

Phase I clinical trials of ticilimumab: Tumor responses are sufficient but not necessary for prolonged survival.

A. Ribas, L. Camacho, J. Gómez-Navarro, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic role of prior cytokine immunotherapy in outcome of treatment with tremelimumab (CP-675,206) in patients with metastatic melanoma

B. Redman, J. Sosman, J. Kirkwood, 2008 .

Safety of tremelimumab (CP-675,206) in patients (pts) with advanced cancer

J. Gómez-Navarro, D. Healey, D. Pavlov, 2008 .

Natural history of diarrhea associated with the anti-CTLA4 monoclonal antibody CP-675,206

B. Redman, J. Sosman, J. Kirkwood, 2007 .

A phase II study of the anti-CTLA4 monoclonal antibody (mAb), CP-675,206, in patients with refractory metastatic adenocarcinoma of the colon or rectum

L. Saltz, A. Venook, L. Fong, 2007 .

Ex vivo blood stimulation assay as a translational research tool in the development of the ticilimumab (CP-675,206).

A. Ribas, L. Camacho, J. Gómez-Navarro, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma

B. Redman, J. Sosman, J. Kirkwood, 2007 .

Dose and schedule selection for the anti-CTLA4 monoclonal antibody ticilimumab in patients (pts) with metastatic melanoma.

A. Ribas, L. Camacho, J. Gómez-Navarro, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

910O Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)

K. Harrington, N. Lee, R. Ferris, 2020, Annals of Oncology.

Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients (pts) with glioblastoma (GBM).

L. Recht, D. Reardon, M. Rosenfeld, 2010 .

The development and validation of a comorbidity index for prostate cancer among Black men.

K. Pearce, S. Fleming, D. Pavlov, 2003, Journal of clinical epidemiology.

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial

T. Brümmendorf, J. Cortes, A. Countouriotis, 2014, British journal of haematology.

Axitinib with or without dose titration for first-line metastatic renal cell carcinoma (mRCC): Unblinded results from a randomized phase II study.

E. Jonasch, M. Fishman, B. Melichar, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma

E. Wang, D. Pavlov, K. Bae, 2014, Journal of clinical pharmacology.

Comorbidities and the Risk of Late-Stage Prostate Cancer

K. Pearce, S. Fleming, D. Pavlov, 2006, TheScientificWorldJournal.

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

A. Hauschild, G. Linette, J. Kirkwood, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.